BR112013015452A2 - composições e métodos para modular fxr - Google Patents
composições e métodos para modular fxrInfo
- Publication number
- BR112013015452A2 BR112013015452A2 BR112013015452A BR112013015452A BR112013015452A2 BR 112013015452 A2 BR112013015452 A2 BR 112013015452A2 BR 112013015452 A BR112013015452 A BR 112013015452A BR 112013015452 A BR112013015452 A BR 112013015452A BR 112013015452 A2 BR112013015452 A2 BR 112013015452A2
- Authority
- BR
- Brazil
- Prior art keywords
- compositions
- methods
- modulating fxr
- fxr
- modulating
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201061425189P | 2010-12-20 | 2010-12-20 | |
US61/425,189 | 2010-12-20 | ||
US201161554297P | 2011-11-01 | 2011-11-01 | |
US61/554,297 | 2011-11-01 | ||
PCT/US2011/062724 WO2012087519A1 (en) | 2010-12-20 | 2011-11-30 | Compositions and methods for modulating fxr |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112013015452A2 true BR112013015452A2 (pt) | 2016-09-20 |
BR112013015452B1 BR112013015452B1 (pt) | 2021-02-02 |
Family
ID=45349296
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013015452-7A BR112013015452B1 (pt) | 2010-12-20 | 2011-11-30 | compostos moduladores de fxr, seus usos, seus intermediários e seu processo de preparação, e composição farmacêutica |
Country Status (38)
Country | Link |
---|---|
US (2) | US9150568B2 (pt) |
EP (1) | EP2655370B1 (pt) |
JP (1) | JP5740483B2 (pt) |
KR (1) | KR101626046B1 (pt) |
CN (1) | CN103443099B (pt) |
AP (1) | AP3414A (pt) |
AR (1) | AR084425A1 (pt) |
AU (1) | AU2011345233B2 (pt) |
BR (1) | BR112013015452B1 (pt) |
CA (1) | CA2819825C (pt) |
CL (1) | CL2013001677A1 (pt) |
CO (1) | CO6801729A2 (pt) |
CR (1) | CR20130307A (pt) |
CU (1) | CU24152B1 (pt) |
CY (1) | CY1119530T1 (pt) |
DK (1) | DK2655370T3 (pt) |
EA (1) | EA025569B1 (pt) |
ES (1) | ES2645728T3 (pt) |
GT (1) | GT201300159A (pt) |
HR (1) | HRP20171615T1 (pt) |
HU (1) | HUE034150T2 (pt) |
IL (1) | IL226853A (pt) |
JO (1) | JO3297B1 (pt) |
LT (1) | LT2655370T (pt) |
MA (1) | MA34767B1 (pt) |
MX (1) | MX338845B (pt) |
MY (1) | MY163216A (pt) |
NZ (1) | NZ613234A (pt) |
PE (1) | PE20140207A1 (pt) |
PL (1) | PL2655370T3 (pt) |
PT (1) | PT2655370T (pt) |
RS (1) | RS56335B1 (pt) |
SG (1) | SG191046A1 (pt) |
SI (1) | SI2655370T1 (pt) |
TW (1) | TWI427078B (pt) |
UY (1) | UY33815A (pt) |
WO (1) | WO2012087519A1 (pt) |
ZA (1) | ZA201304044B (pt) |
Families Citing this family (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020183388A1 (en) | 2019-03-13 | 2020-09-17 | Novartis Ag | Pharmaceutical composition |
JP2014500318A (ja) * | 2010-12-20 | 2014-01-09 | アイアールエム・リミテッド・ライアビリティ・カンパニー | ファルネソイドx受容体を調節するための組成物および方法 |
CU24152B1 (es) * | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
SG11201408284VA (en) | 2012-05-22 | 2015-02-27 | Xenon Pharmaceuticals Inc | N-substituted benzamides and their use in the treatment of pain |
CN103007081B (zh) * | 2012-11-27 | 2013-12-04 | 鞠法红 | 一种治疗非酒精性脂肪肝的中药组合物 |
CA2901427A1 (en) | 2013-03-07 | 2014-09-12 | Califia Bio, Inc. | Mixed lineage kinase inhibitors and method of treatments |
HUE039155T2 (hu) * | 2013-11-05 | 2018-12-28 | Novartis Ag | Készítmények és eljárások farnezoid X receptorok modulálására |
EP3034499A1 (en) | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Novel FXR (NR1H4) modulating compounds |
EP3034501A1 (en) | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Hydroxy containing FXR (NR1H4) modulating compounds |
WO2016097933A1 (en) * | 2014-12-18 | 2016-06-23 | Novartis Ag | Azabicyclooctane derivatives as fxr agonists for use in the treatment of liver and gastrointestinal diseases |
TWI698430B (zh) | 2015-02-13 | 2020-07-11 | 南北兄弟藥業投資有限公司 | 三環化合物及其在藥物中的應用 |
NZ735126A (en) | 2015-03-31 | 2022-10-28 | Enanta Pharm Inc | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof |
CN106146483A (zh) * | 2015-04-23 | 2016-11-23 | 上海迪诺医药科技有限公司 | 杂环类法尼酯衍生物x受体调节剂 |
CN106946867B (zh) * | 2016-01-06 | 2019-11-12 | 广州市恒诺康医药科技有限公司 | Fxr受体调节剂及其制备方法和用途 |
CN108602811B (zh) * | 2016-02-01 | 2021-11-16 | 轩竹生物科技有限公司 | Fxr受体激动剂 |
JP2019504850A (ja) * | 2016-02-08 | 2019-02-21 | レデックス ファーマ ピーエルシーRedx Pharma Plc | 複素環式化合物、特に2−オキソ−4,4,5,5,6,6,7,7−オクタヒドロベンズオキサゾール誘導体、および抗菌化合物としてのこれらの使用 |
SI3419624T1 (sl) * | 2016-02-22 | 2021-05-31 | Novartis Ag | Postopki za uporabo agonistov FXR |
CN108697704A (zh) | 2016-02-22 | 2018-10-23 | 诺华股份有限公司 | 使用fxr激动剂的方法 |
RU2743075C2 (ru) | 2016-02-22 | 2021-02-15 | Новартис Аг | Способы применения агонистов fxr |
WO2017189652A1 (en) | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
US10080742B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
WO2017189663A1 (en) | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
WO2017201152A1 (en) * | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
US10144729B2 (en) | 2016-05-18 | 2018-12-04 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as FXR agonists and methods of use thereof |
WO2017201155A1 (en) * | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | lSOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF |
AR108711A1 (es) * | 2016-06-13 | 2018-09-19 | Gilead Sciences Inc | Compuestos moduladores de fxr (nr1h4) |
CA2968836A1 (en) | 2016-06-13 | 2017-12-13 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
EP3730487B1 (en) | 2016-06-13 | 2022-04-27 | Gilead Sciences, Inc. | Azetidine derivatives as fxr (nr1h4) modulators |
TW201808283A (zh) | 2016-08-05 | 2018-03-16 | 廣東東陽光藥業有限公司 | 含氮三環化合物及其在藥物中的應用 |
MA46052A (fr) * | 2016-08-23 | 2021-03-17 | Ardelyx Inc | Modulateurs du récepteur hormonal pour le traitement d'états et de troubles métaboliques |
US11091482B2 (en) | 2016-08-23 | 2021-08-17 | Ardelyx, Inc. | Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators |
AU2017317988B2 (en) | 2016-08-31 | 2020-12-24 | Jiangsu Hengrui Medicine Co., Ltd. | Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereof |
JOP20190040A1 (ar) * | 2016-09-14 | 2019-03-10 | Novartis Ag | توليفة من ناهضات fxr |
JP6915050B2 (ja) * | 2016-09-14 | 2021-08-04 | ノバルティス アーゲー | Fxrアゴニストの新規のレジーム |
CN108430998B (zh) * | 2016-09-28 | 2021-07-09 | 四川科伦博泰生物医药股份有限公司 | 氮杂双环衍生物及其制备方法和用途 |
MX2019003790A (es) * | 2016-10-04 | 2019-09-26 | Enanta Pharm Inc | Analogos de isoxazol como agonistas de fxr y metodos de uso de los mismos. |
US10597391B2 (en) | 2016-10-26 | 2020-03-24 | Enanta Pharmaceuticals, Inc. | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof |
CN108017636A (zh) * | 2016-11-04 | 2018-05-11 | 合帕吉恩治疗公司 | 作为fxr调节剂的含氮杂环化合物 |
WO2018153933A1 (en) | 2017-02-21 | 2018-08-30 | Genfit | Combination of a ppar agonist with a fxr agonist |
KR20190126920A (ko) | 2017-03-28 | 2019-11-12 | 길리애드 사이언시즈, 인코포레이티드 | 간 질환을 치료하기 위한 치료 조합물 |
CA3059869C (en) | 2017-04-12 | 2022-01-04 | Il Dong Pharmaceutical Co., Ltd. | Isoxazole derivatives as nuclear receptor agonists and uses thereof |
WO2018190643A1 (en) * | 2017-04-12 | 2018-10-18 | Il Dong Pharmaceutical Co., Ltd. | An isoxazole derivatives as nuclear receptor agonists and used thereof |
CN109265471B (zh) * | 2017-06-30 | 2021-06-04 | 轩竹生物科技有限公司 | Fxr受体激动剂 |
AU2018298253B2 (en) * | 2017-07-06 | 2020-11-19 | Xuanzhu Biopharmaceutical Co., Ltd. | FXR receptor agonist |
CN109320517B (zh) * | 2017-07-31 | 2021-08-17 | 轩竹生物科技有限公司 | Fxr受体激动剂 |
AR114930A1 (es) * | 2017-09-12 | 2020-11-11 | Novartis Ag | Composición farmacéutica |
WO2019055808A1 (en) * | 2017-09-14 | 2019-03-21 | Ardelyx, Inc. | HORMONE RECEPTOR MODULATORS FOR THE TREATMENT OF MUTAGENIC AND FIBROTIC METABOLIC CONDITIONS AND DISORDERS |
EP3704112B1 (en) | 2017-11-01 | 2023-09-27 | Bristol-Myers Squibb Company | Alkene spirocyclic compounds as farnesoid x receptor modulators |
EA202091101A1 (ru) * | 2017-11-01 | 2020-08-06 | Бристол-Маерс Сквибб Компани | Спироциклические соединения в качестве модуляторов фарнезоидного x-рецептора |
US11370785B2 (en) | 2017-11-01 | 2022-06-28 | Bristol-Myers Squibb Company | Multicyclic compounds as farnesoid X receptor modulators |
ES2944657T3 (es) * | 2017-11-01 | 2023-06-23 | Bristol Myers Squibb Co | Compuestos de alqueno como moduladores del receptor farnesoide X |
EA202091063A1 (ru) | 2017-11-01 | 2020-09-18 | Бристол-Маерс Сквибб Компани | Мостиковые бициклические соединения в качестве модуляторов фарнезоидного х-рецептора |
US20190161483A1 (en) | 2017-11-30 | 2019-05-30 | Novartis Ag | Methods for using fxr agonists |
US10689391B2 (en) | 2017-12-12 | 2020-06-23 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as FXR agonists and methods of use thereof |
EP3730491B1 (en) | 2017-12-22 | 2022-07-20 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Isoxazole derivative, preparation method therefor, and use thereof |
CN110128432B (zh) | 2018-02-02 | 2021-03-02 | 广东东阳光药业有限公司 | 含氮三环化合物及其在药物中的应用 |
WO2019160813A1 (en) | 2018-02-14 | 2019-08-22 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
CN110357875B (zh) * | 2018-04-10 | 2022-06-21 | 浙江海正药业股份有限公司 | 氮杂双环辛烷类衍生物、其制备方法及其在医药上的用途 |
CA3100635A1 (en) | 2018-05-31 | 2019-12-05 | Novartis Ag | Combinations comprising tropifexor and cenicriviroc |
TWI707683B (zh) | 2018-06-13 | 2020-10-21 | 美商輝瑞股份有限公司 | Glp-1受體促效劑及其用途 |
WO2020001304A1 (zh) * | 2018-06-26 | 2020-01-02 | 轩竹(海南)医药科技有限公司 | Fxr受体激动剂 |
CN111868056B (zh) * | 2018-07-11 | 2023-02-03 | 中国医药研究开发中心有限公司 | 1,2,4-噁二唑类化合物及其制备方法和医药用途 |
SG11202012321PA (en) | 2018-07-25 | 2021-02-25 | Novartis Ag | Nlrp3 inflammasome inhibitors |
BR112021002050A2 (pt) | 2018-08-08 | 2021-05-04 | Inorbit Therapeutics Ab | composto, composição farmacêutica, e, métodos para modular e ativar um receptor farsenoide x (fxr) e para tratar e/ou prevenir uma doença ou transtorno |
TWI718644B (zh) | 2018-08-31 | 2021-02-11 | 美商輝瑞股份有限公司 | 用於治療nash/nafld和相關疾病之組合 |
EA202191566A1 (ru) | 2019-01-15 | 2021-11-01 | Джилид Сайенсиз, Инк. | Соединения, модулирующие fxr (nr1h4) |
EP3919489A4 (en) * | 2019-01-31 | 2022-10-12 | The National Institutes of Pharmaceutical R&D Co., Ltd | AROMATIC RING OR HETEROAROMATIC RING COMPOUNDS, PROCESS FOR THEIR PRODUCTION AND MEDICAL USE |
AR118050A1 (es) | 2019-02-15 | 2021-09-15 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x |
CA3129949C (en) | 2019-02-19 | 2024-04-30 | Gilead Sciences, Inc. | Solid forms of fxr agonists |
CN111825701B (zh) * | 2019-04-19 | 2023-12-08 | 正大天晴药业集团股份有限公司 | 含苯并噻唑的三环类fxr调节剂化合物 |
JP7398605B2 (ja) * | 2019-04-19 | 2023-12-15 | シャンハイ インスティチュート オブ マテリア メディカ,チャイニーズ アカデミー オブ サイエンシーズ | Fxr小分子アゴニストとその調製方法および用途 |
CN111825667B (zh) * | 2019-04-19 | 2023-07-25 | 中国科学院上海药物研究所 | Fxr小分子激动剂及其制备方法和用途 |
WO2020231917A1 (en) | 2019-05-13 | 2020-11-19 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
AR119731A1 (es) | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
CN113874019A (zh) | 2019-05-20 | 2021-12-31 | 辉瑞大药厂 | 用于治疗nash/nafld及相关疾病的包含作为glp-1r激动剂的苯并二氧杂环戊烯的组合 |
JP2022540699A (ja) | 2019-07-18 | 2022-09-16 | ウエヌイグレックオ・ファーマ | インターフェロンの有害作用を減少させる方法 |
CN114080234A (zh) | 2019-07-23 | 2022-02-22 | 诺华股份有限公司 | 包含fxr激动剂的治疗 |
US20220265619A1 (en) | 2019-07-23 | 2022-08-25 | Novartis Ag | Combination treatment of liver diseases using fxr agonists |
WO2021044351A1 (en) | 2019-09-06 | 2021-03-11 | Novartis Ag | Methods of treating liver disease using lta4h inhibitors |
US20220347190A1 (en) | 2019-09-19 | 2022-11-03 | Novartis Ag | Treatment comprising fxr agonists |
US20220331341A1 (en) | 2019-09-30 | 2022-10-20 | Novartis Ag | Treatment comprising the use of fxr agonists |
CN114728954B (zh) * | 2019-11-29 | 2023-10-17 | 广东东阳光药业股份有限公司 | Tropifexor的新晶型及其制备方法 |
WO2021104021A1 (zh) * | 2019-11-29 | 2021-06-03 | 广东东阳光药业有限公司 | Tropifexor的新晶型及其制备方法 |
EP4073028A1 (en) | 2019-12-10 | 2022-10-19 | Pfizer Inc. | Solid forms of 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d] [1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d] imidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt |
KR20220121838A (ko) | 2019-12-20 | 2022-09-01 | 노파르티스 아게 | 인테그린 억제제를 사용한 간 질환의 조합 치료 |
WO2021133948A1 (en) | 2019-12-23 | 2021-07-01 | Axcella Health Inc. | Compositions and methods for the treatment of liver diseases and disorders |
JP2023510274A (ja) | 2020-01-15 | 2023-03-13 | アンセルム(アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル) | D型肝炎ウイルスによる感染を処置するためのfxrアゴニストの使用 |
CN115348863A (zh) | 2020-03-27 | 2022-11-15 | 辉瑞公司 | 以2-[(4-{6-[(4-氰基-2-氟苄基)氧基]吡啶-2-基}哌啶-1-基)甲基]-1-[(2s)-氧杂环丁烷-2-基甲基]-1h-苯并咪唑-6-甲酸或其药学上的盐治疗2型糖尿病或肥胖症或体重过重 |
WO2021233461A1 (zh) * | 2020-05-22 | 2021-11-25 | 苏州晶云药物科技股份有限公司 | 苯并噻唑类化合物的新晶型及其制备方法 |
EP4161925A1 (en) * | 2020-06-09 | 2023-04-12 | Viking Therapeutics, Inc. | Compositions and methods for the treatment of liver disorders |
MX2023002850A (es) | 2020-09-10 | 2023-07-07 | Precirix N V | Fragmento de anticuerpo contra proteina activadora de fibroblastos (fap). |
CN114315830A (zh) * | 2020-09-30 | 2022-04-12 | 中国科学院上海药物研究所 | Fxr小分子激动剂及其制备方法和用途 |
AU2022209084A1 (en) | 2021-01-14 | 2023-08-10 | Centre Leon Bérard | Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection |
CN113024552B (zh) * | 2021-03-26 | 2022-08-05 | 厦门市博瑞来医药科技有限公司 | 一类新型非甾体fxr激动剂的合成及其应用 |
CN113292555B (zh) * | 2021-04-28 | 2022-03-18 | 武汉纽瑞斯医药科技有限公司 | 一种Tropifexor的制备方法 |
CA3213217A1 (en) | 2021-04-28 | 2022-11-03 | Raphael Darteil | Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment |
CA3230347A1 (en) | 2021-08-31 | 2023-03-09 | Pfizer Inc. | Solid forms of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt |
EP4245365A1 (en) * | 2022-03-16 | 2023-09-20 | Cascade Pharmaceuticals, Inc. | A fxr small molecule agonist, the preparation and use thereof |
WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
WO2023213801A1 (en) | 2022-05-02 | 2023-11-09 | Precirix N.V. | Pre-targeting |
WO2023228023A1 (en) | 2022-05-23 | 2023-11-30 | Pfizer Inc. | Treatment of type 2 diabetes or weight management control with 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d]imidazole-6-carboxylic acid or a pharmaceutically salt thereof |
TW202408494A (zh) * | 2022-06-30 | 2024-03-01 | 南韓商日東製藥股份有限公司 | 異噁唑衍生物及其鹽的新晶型以及包括其之醫藥組合物 |
TW202406550A (zh) | 2022-08-03 | 2024-02-16 | 瑞士商諾華公司 | Nlrp3炎性小體抑制劑 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
JPH0672123B2 (ja) | 1986-08-21 | 1994-09-14 | セントラル硝子株式会社 | トリフルオロメチル基を有するシクロヘキサンカルボン酸の製造方法 |
WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
WO2004048349A1 (en) | 2002-11-22 | 2004-06-10 | Smithkline Beecham Corporation | Farnesoid x receptor agonists |
CA2627089A1 (en) | 2005-11-09 | 2007-05-18 | Memory Pharmaceuticals Corporation | 1 h-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof |
JP2009517453A (ja) | 2005-12-02 | 2009-04-30 | ファイザー・リミテッド | Pde7阻害剤としてのスピロ環式キナゾリン誘導体 |
CN101374834B (zh) * | 2006-02-03 | 2011-12-14 | 伊莱利利公司 | 用于调节fxr的化合物和方法 |
JP2007230909A (ja) * | 2006-03-01 | 2007-09-13 | Univ Of Tokyo | 置換イソキサゾール誘導体 |
AU2007267692B2 (en) | 2006-05-24 | 2012-06-14 | Eli Lilly And Company | Compounds and methods for modulating FXR |
EP1894924A1 (en) * | 2006-08-29 | 2008-03-05 | Phenex Pharmaceuticals AG | Heterocyclic FXR binding compounds |
US20110034507A1 (en) * | 2007-07-02 | 2011-02-10 | Smithkline Beecham Corporation | Farnesoid x receptor agonists |
TW200906823A (en) * | 2007-07-16 | 2009-02-16 | Lilly Co Eli | Compounds and methods for modulating FXR |
JP2011500727A (ja) | 2007-10-22 | 2011-01-06 | シェーリング コーポレイション | Gpr119の活性のモジュレーターとしての二環式ヘテロ環誘導体およびその使用 |
EP2289883A1 (en) * | 2009-08-19 | 2011-03-02 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
US9409918B2 (en) | 2009-10-29 | 2016-08-09 | Merck Sharp & Dohme Corp. | Bridged bicyclic piperidine derivatives and methods of use thereof |
CN103391937A (zh) | 2010-12-20 | 2013-11-13 | Irm责任有限公司 | 用于调控法尼醇x受体的组合物和方法 |
JP2014500318A (ja) | 2010-12-20 | 2014-01-09 | アイアールエム・リミテッド・ライアビリティ・カンパニー | ファルネソイドx受容体を調節するための組成物および方法 |
CU24152B1 (es) * | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
-
2011
- 2011-10-30 CU CU20130082A patent/CU24152B1/es active IP Right Grant
- 2011-11-30 KR KR1020137019136A patent/KR101626046B1/ko active IP Right Grant
- 2011-11-30 AP AP2013006926A patent/AP3414A/xx active
- 2011-11-30 EA EA201390934A patent/EA025569B1/ru not_active IP Right Cessation
- 2011-11-30 PL PL11796872T patent/PL2655370T3/pl unknown
- 2011-11-30 JP JP2013546165A patent/JP5740483B2/ja not_active Expired - Fee Related
- 2011-11-30 WO PCT/US2011/062724 patent/WO2012087519A1/en active Application Filing
- 2011-11-30 HU HUE11796872A patent/HUE034150T2/en unknown
- 2011-11-30 SI SI201131307T patent/SI2655370T1/sl unknown
- 2011-11-30 MX MX2013007180A patent/MX338845B/es active IP Right Grant
- 2011-11-30 RS RS20170867A patent/RS56335B1/sr unknown
- 2011-11-30 NZ NZ61323411A patent/NZ613234A/en not_active IP Right Cessation
- 2011-11-30 SG SG2013043864A patent/SG191046A1/en unknown
- 2011-11-30 LT LTEP11796872.7T patent/LT2655370T/lt unknown
- 2011-11-30 CA CA2819825A patent/CA2819825C/en active Active
- 2011-11-30 CN CN201180067346.8A patent/CN103443099B/zh not_active Expired - Fee Related
- 2011-11-30 MY MYPI2013002124A patent/MY163216A/en unknown
- 2011-11-30 US US13/993,138 patent/US9150568B2/en active Active
- 2011-11-30 AU AU2011345233A patent/AU2011345233B2/en not_active Ceased
- 2011-11-30 EP EP11796872.7A patent/EP2655370B1/en active Active
- 2011-11-30 ES ES11796872.7T patent/ES2645728T3/es active Active
- 2011-11-30 PT PT117968727T patent/PT2655370T/pt unknown
- 2011-11-30 PE PE2013001456A patent/PE20140207A1/es active IP Right Grant
- 2011-11-30 DK DK11796872.7T patent/DK2655370T3/da active
- 2011-11-30 BR BR112013015452-7A patent/BR112013015452B1/pt not_active IP Right Cessation
- 2011-12-18 JO JOP/2011/0386A patent/JO3297B1/ar active
- 2011-12-19 UY UY33815A patent/UY33815A/es not_active Application Discontinuation
- 2011-12-20 TW TW100147534A patent/TWI427078B/zh not_active IP Right Cessation
- 2011-12-20 AR ARP110104800 patent/AR084425A1/es active IP Right Grant
-
2013
- 2013-06-03 ZA ZA2013/04044A patent/ZA201304044B/en unknown
- 2013-06-10 IL IL226853A patent/IL226853A/en active IP Right Grant
- 2013-06-11 CL CL2013001677A patent/CL2013001677A1/es unknown
- 2013-06-19 GT GT201300159A patent/GT201300159A/es unknown
- 2013-06-20 CR CR20130307A patent/CR20130307A/es unknown
- 2013-06-28 MA MA36062A patent/MA34767B1/fr unknown
- 2013-07-08 CO CO13160561A patent/CO6801729A2/es not_active Application Discontinuation
-
2015
- 2015-07-30 US US14/813,397 patent/US20150366856A1/en not_active Abandoned
-
2017
- 2017-10-24 HR HRP20171615TT patent/HRP20171615T1/hr unknown
- 2017-11-02 CY CY20171101146T patent/CY1119530T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013015452A2 (pt) | composições e métodos para modular fxr | |
BR112014010660A2 (pt) | métodos e composições para modular bactéria gastrointestinal | |
BR112013007496A2 (pt) | composições e métodos para termo modulação específica | |
BR112012031446A2 (pt) | componentes e métodos para implantes | |
BR112013032426A2 (pt) | composições probióticas e métodos | |
DK2763665T3 (da) | Antimikrobielle sammensætninger og fremgangsmåder til anvendelse deraf | |
BR112014009528A2 (pt) | métodos e composições para tratar eritropoiese ineficaz | |
BR112012017441A2 (pt) | compostos e métodos | |
PT2665486T (pt) | Composições para modular a atividade das citocinas gama-c | |
BR112013019280A2 (pt) | composições wnt e métodos para sua utilização | |
BRPI1008326A2 (pt) | Composições e métodos para controlar nanatódeos | |
BR112014010450A2 (pt) | composição e método | |
BR112013015781A2 (pt) | compostos e métodos para reparação da pele | |
EP2760887A4 (en) | COMPOSITIONS AND METHODS OF HEMOSTASE MODULATION | |
BR112013015107A2 (pt) | métodos e dispositivos para usar álcool isoperílico | |
CO6781494A2 (es) | Composición lubricante y método para su preparación | |
BR112013011469A2 (pt) | métodos e composições para secar carvão | |
BR112014010860A2 (pt) | composição e método | |
BR112013013901A2 (pt) | gerador eletromagnético e método para sua utilização | |
BR112014010769A2 (pt) | métodos e composições para neuroproteção | |
BR112013012843A2 (pt) | composições e métodos para o suprimento de nutriente | |
BR112013019707A2 (pt) | métodos e composições antinematóides | |
BR112013008812A2 (pt) | composição e método | |
BR112012029669A2 (pt) | composição e método | |
CO6990712A2 (es) | Combinación farmacéutica antineuritica y composiciones |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) |
|
B25A | Requested transfer of rights approved |
Owner name: NOVARTIS AG (CH) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/11/2011, OBSERVADAS AS CONDICOES LEGAIS. |
|
B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 12A ANUIDADE. |
|
B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2751 DE 26-09-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |